Amundi
MDGL icon

Amundi’s Madrigal Pharmaceuticals MDGL Stock Holding History

Amundi’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$744K Buy
1,386
+162
+13% +$83K ﹤0.01% 1497
2026
Q1 		$641K Buy
1,224
+787
+180% +$376K ﹤0.01% 1450
2025
Q4 		$254K Buy
+437
New +$223K ﹤0.01% 1693
2022
Q4 		– Sell
-1,249
Closed -$91K – 1947
2022
Q3 		$91K Hold
1,249
– – ﹤0.01% 1575
2022
Q2 		$85K Buy
+1,249
New +$91.8K ﹤0.01% 1476

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amundi's MDGL Position: Q2 2026 in Review

Amundi increased its Madrigal Pharmaceuticals (MDGL) stake by 13% in Q2 2026, buying an estimated $83K and bringing the position to 1,386 shares worth $744K. The position accounts for ﹤0.01% of the portfolio, ranked #1497.

Amundi first reported a position in MDGL in Q2 2022 and has held it in 5 quarters since. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Amundi held 1,386 shares of Madrigal Pharmaceuticals worth $744K as of Q2 2026.
  • Amundi bought 162 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $83K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1497 holding.
  • Amundi first reported a position in Madrigal Pharmaceuticals in Q2 2022 and has held it in 5 quarters since.
  • 415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.